Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPM31510 in epidermolysis bullosa
NCT02793960Phase 1Completed
- Start
- Aug 2016
- Primary completion
- Aug 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ubidecarenone nanodispersion in epidermolysis bullosa (EB). Primary endpoint: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment at 16 weeks. Started Aug 2016; status: completed.
02
Drugs
ubidecarenone nanodispersion
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT02793960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02793960.